Not medical advice
The content on qsymia.us.com is educational drug information. It is not medical advice, does not establish a physician–patient relationship, and is not a substitute for consultation with a licensed healthcare provider. Do not start, stop, or alter any prescription medication based on what you read here. Medication decisions — including any decision involving Qsymia, phentermine/topiramate, or GLP-1 medications discussed on this site — should be made in partnership with a US-licensed clinician who can evaluate your personal medical history, current medications, and contraindications.
If you are already taking Qsymia at the higher dose (11.25/69 or 15/92), do not stop abruptly. Abrupt discontinuation of topiramate can lower seizure threshold and precipitate rebound symptoms. Any change in therapy should be supervised by a clinician.
Controlled-substance notice
Qsymia contains phentermine, a Schedule IV controlled substance under the federal Controlled Substances Act, with recognized potential for abuse and dependence. Qsymia is subject to a Risk Evaluation and Mitigation Strategy (REMS) program required by the FDA because fetal exposure to topiramate during the first trimester of pregnancy is associated with an increased risk of oral clefts. Patients of reproductive potential must use effective contraception throughout therapy and receive pregnancy testing before and during treatment. Qsymia is legally available only through REMS-certified prescribers and pharmacies.
Affiliate disclosure
This website contains paid affiliate links to US-licensed telehealth platforms that can prescribe FDA-approved GLP-1 medications (semaglutide, tirzepatide, liraglutide) after a clinician review. When a reader enrolls or purchases through one of these links, qsymia.us.com may earn a referral commission at no additional cost to the reader. Affiliate arrangements support the editorial operation of this site. They do not influence the factual coverage of Qsymia on this site — drug comparisons and recommendations are based on published clinical trial data and FDA-approved labeling.
We are not affiliated with Currax Pharmaceuticals, Vivus, Inc., or any other manufacturer of Qsymia or GLP-1 medications.
Drug information and trademarks
Qsymia® is a registered trademark of Currax Pharmaceuticals, which acquired the product from Vivus, Inc. qsymia.us.com is an independent educational publisher and has no commercial relationship with Currax, Vivus, or any medication manufacturer mentioned on this site. All brand names used are the property of their respective owners.
All drug data — indications, dosing, side effects, contraindications, warnings, pharmacokinetics, and drug interactions — is sourced from the most current FDA-approved prescribing information available at the time of writing or revision, and from peer-reviewed published clinical trials. Prescribing information can change; always verify current labeling with your clinician or pharmacist.
Comparison methodology
Head-to-head comparisons between Qsymia and other anti-obesity medications on this site rely on each drug's own FDA registration trial (CONQUER, EQUIP, SEQUEL for Qsymia; STEP 1 for Wegovy; SURMOUNT-1 for Zepbound; SCALE for Saxenda; COR-I for Contrave). These are cross-trial comparisons across different study populations and durations, not head-to-head trials. Direct head-to-head trials between Qsymia and the GLP-1 class are limited. Percent weight loss values reported are placebo-subtracted and reflect intent-to-treat populations.
Individual results vary substantially. A published mean of 10% weight loss does not guarantee any individual patient will achieve that result, and the distribution around the mean is wide.
Prices and availability
Drug pricing data on this site reflects public discount-card quotes, manufacturer list prices, and telehealth program pricing available at the time of writing. Prices change frequently and vary by pharmacy, ZIP code, insurance coverage, and dose. Verify current pricing at the point of purchase. Insurance coverage for weight-loss medications is also subject to change based on employer plan design and CMS rulings.
No guarantee
Although we make reasonable effort to ensure accuracy, medicine evolves and this site may contain errors, omissions, or out-of-date information. qsymia.us.com and its editorial team make no warranties, express or implied, regarding the accuracy, completeness, or fitness for a particular purpose of the content on this site. Users rely on the information at their own discretion.
Contact and corrections
Factual corrections or editorial feedback are welcome. See our About page for how to reach us. We do not provide individual medical consultations, case-specific advice, or prescribing decisions under any circumstances.